Turkey: Key Developments And Predictions For Patent Law In Turkey – 2019

Last Updated: 22 May 2019
Article by Gun and Partners

When the Industrial Property Law came into force on 10 January 2017, the introduction of the post grant opposition procedure for national patent applications or the new "satisfying national market's need" criteria concerning compulsory license due to non-use of the patent appeared to be of the most significance. However, as usual, the devil was hidden in the detail. When we first put the new law into practice, we experienced that other provisions such as the use requirement of patents and filing a declaration on use before the Turkish Patent Office or employee inventions can have many different interpretations. Meanwhile, Discovery of Evidence and Preliminary Injunction (PI), Damages, Bolar Exemption, Impact of EPO Opposition on National Proceedings remained the hottest topics in relation to Patent litigation in Turkey. It is worth noting also that the Judges appointed to IP Courts from other civil courts, and particularly from the commercial courts, interpreted the sole Discovery of Evidence (without PI demand) demands more positively. In respect of the patent right holder, this approach would mean that they would have greater benefit if the Court discovered and determined the evidence on infringement of the patent before taking the enforcement action on merit. This Paper provides an outline of the key aspects of patent litigation in Turkey and the most important or challenging issues in Turkish Patent Law.

Declaration of Use and Compulsory License 

The new IP Law ('the Law') numbered 6769 abolished the provisions on "the use requirement of patents" and "the evidence of use" of the Decree Law Pertaining to the Protection of Patent Rights. The Law now focuses on the requirements of use for patents within the provision of a Compulsory License.

Accordingly, a patent owner must make use of the patented invention within three years following publication of its granted decision in the Official Bulletin ('the Bulletin') or within four years from the date of its application, whichever is the latest to expire. The Bulletin is a type of announcement, which shows when a patent is not being used. Third parties will then be aware that they can request a license over such patent.

When assessing actual 'use', market conditions and conditions outside the control of the patent owner, such as the need for pharmaceutical marketing authorisation, compliance with standards and the lack of new applications in alternative fields should be considered. At the end of the prescribed terms, any interested party can request a compulsory license on the grounds that the patented invention is not being used or no serious and real measures have been taken to make use of the patented invention or the level of current use does not meet domestic demand.

The same applies to cases where there has been no use of a patent for more than three years without justified reason.

Additionally, patent holders are requested to file a declaration of use of the patent before the Turkish Patent Office ('the Office'). The Regulation on the Implementation of the Law rules that the declaration of the use of a patent should be submitted to the Office in accordance with the same legal terms as prescribed in the Law. Patents that have not been notified of their use within this period will be published in the Bulletin. The publication, however, does not lead to any direct negative consequences or benefits. Even if a patent was not listed in the list of non-used patents, a third party may still request a compulsory license, claiming that the patent is not used or no serious and real measures have been taken to make use of the patented invention or the level of current use does not satisfy domestic demand. Even if the patent is listed, it does not mean there will be an automatic grant of a compulsory license.

When requesting a compulsory license, there is a court procedure to follow, and the declaration of the patent's use filed before the Office can only be used as an indication of its use. The lack of such declaration does not affect the court procedure as the use can also be proven during court proceedings.

Employee Inventions

On 29 September 2017, the Regulation on Employee Inventions, Inventions Realised within Higher Education Institutions and Inventions Arisen from Projects Supported by Public Authorities ("the Regulation") came into force. This regulates the method used to determine compensation awarded to employees should their employer demand a full or partial right to their invention. The regulation stipulates the methods to be used to calculate the employee's award, which should be reasonable.

In principle, compensation will be determined via an agreement between both parties. Where there is a dispute, especially if the revenue of the invention cannot be determined, compensation can be determined by a comparison with other similar inventions, the potential profit resulting from the invention or according to a reasonable amount that the employer would pay, if he/she wanted to purchase it. In addition, revenue from inventions can be considered equal to revenue earned from a license or to the revenue received from the sale of the invention.

According to Turkish IP Law, when the employer claims the right to a work-related invention, they cannot refuse to pay the inventor compensation if they believe that the invention is not worth protecting.

However, if the patent is invalidated in an action filed against the patent before a competent Court, the employee can no longer request compensation. The lack of clarity in this provision has led to some employers having third parties file invalidation actions (on their behalf) against the patent so they can avoid paying the employee compensation. However, the relevant rule has now been clarified in that the period leading up to the finalisation of the invalidation action will be taken into consideration when calculating the employee's compensation.

Any dispute within the scope of the Regulation must be resolved via arbitration, which should either be agreed by both parties or it will be enforced by law. That said, there is a pending administrative lawsuit to cancel the arbitration provision of the Regulation, on the grounds that a mandatory arbitration must be imposed by law, not by an administrative regulation.

Post-Grant Opposition System 

The post-grant opposition system was first introduced in the new IP Law, which came into force in January 2017. It is mostly aligned with the system regulated in Article 101 of the European Patent Convention ('EPC').

Accordingly, third parties are entitled to file oppositions against a patent within 6 months from the grant decision as published in the Bulletin. The patent holder may respond to the opposition within 3 months from this date and/or may file amendments. The Re-Examination and Re-Evaluation Board evaluates the opposition and the response from the patent holder and makes a decision on maintaining or revocation of the patent.

With regards to the post-grant opposition system, the Law also governs what happens in cases where an invalidation action is filed before the IP courts when an opposition on the same patent is pending. The Law states that the Court cannot issue a decision on the invalidation action until the outcome of the opposition has been published in the Bulletin or it has been confirmed that no opposition has been filed against the patent.

Unfortunately, the provision covers only national filings. It is at the discretion of the IP Court whether to delay the invalidation proceedings against a national validation of a European Patent; in cases where a post-grant opposition is pending before the EPO.

On the other hand, one key feature of the post-granted opposition system has not been included in the Law. The Law prohibits any amendment or limitation of the patent following the outcome of the patent office proceedings. This means that a patent can be amended or limited only during the examination or opposition procedures before the patent office. This provision explicitly precludes the possibility of amending or limiting a patent during invalidity proceedings. As well as being inconsistent with Article 138/(3) of the EPC and creating discrimination between European patents validated in Turkey and national filings, this provision makes the post-grant opposition system useless, or at least vulnerable to be used in bad faith. However, it is inevitable that third parties will prefer to challenge the patent via an invalidation action, where the patent holder will have no right to amend or limit the patent, rather than via an opposition, where the patent holder may be able to maintain its patent through permissible amendments and limitations.

Discovery of Evidence and Preliminary Injunction

Patent holders may initiate temporary legal protection measures by filing for discovery of evidence ("DoE") and/or a preliminary injunction ("PI"). PI requests may be placed either in an infringement action (at any time and any number of times) or preceding the infringement action as a standalone temporary measure application. Conditions and requirements to seek and obtain a PI are briefly; (i) prima facie illegality (i.e. infringement or a potential danger); and (ii) irreparable harm or damage if it is not prevented by a PI.

If it is filed as a standalone application and the Court grants a PI in favour of the party requesting the DoE and/or PI, the requesting party must file a main action for patent infringement within two weeks from the date of the delivery of the PI order. Otherwise, the PI order is automatically lifted. It may also be noted that a dismissal of an infringement action may cripple the patent holder until there is a change in circumstances and when there is a further standing to file an action. Dismissal of PI requests on the other hand has no such downside. Processing of DoE and PI applications may take between 3-4 weeks to 3-4 months depending on the complexity of the infringement issue and the time the Court appointed experts take to prepare their expert report.

Where the court rules in favour of a PI, the patent holder is usually ordered to deposit a bond, which may vary depending on the value of the product in question. The bond would remain in place for the duration of the PI. If the PI turns out to have been unfairly granted, the bond is then utilised towards an action for damages, which may be filed by the defendant.

Bolar Exemption in Pharmaceutical Patent Litigation

Article 85/III(c) of the Intellectual Property Law (IP Law) ensures pending marketing authorisation applications for medicinal products are exempt from patent infringement. Unfortunately, the limits of the Bolar Exemption is not so clear. Although the process and act of licensing (obtaining marketing authorisation) are exempt, the IP Courts are more frequently requesting further commercial activities by generic companies before hearing a DoE / PI or any infringement claim. Any promotional activities or attempts to sell or offer for sale such as applications for reimbursement and obtaining regulatory price approvals may be accepted as evidence, although they are not conclusive.

Impact of EPO Opposition on National Actions

Ever since Turkey became a member of the EPC, a hot topic has been the enforcement or invalidity of Turkish validation of European Patent(s) (EP) while proceedings before the European Patent Office (EPO) are pending.

Once an EP is validated in Turkey, it becomes a national patent three months from its first granted decision by the Examination Board of the EPO. For EPs, the Turkish Patent and Trademark Office (TPMO) acts as a procedural agency only. Thus, the TPMO does not examine the EPs at any level nor it does it hear any post-grant oppositions. On the other hand, the Law has two provisions that contradict with the EPC. The first is that a patent may be subject to invalidity proceedings before Turkish IP Courts since the granted decision. While Courts cannot decide on an invalidation action until the national opposition proceedings come to an end, there is no such immunity for EPs. The other is that no claim amendment is allowed following the grant. EPs validated in Turkey are directly exposed to invalidation actions, in spite of the fact that they may be amended during EPO opposition proceedings, which will be automatically reflected to the Turkish validation.

To avoid any Turkish Court decision on validity, EP owners are advised to ask the Court to wait for the outcome of the EPO opposition proceedings.

If this is not accepted by the Court due to the length of the EPO proceedings, it is worth asking the Court to apply Article 138/3 of the EPC.

Article 138/3 of EPC is binding for the national Court to allow EP holders to limit the patent by amendment and that the patent as thus limited will form the basis for the invalidation proceedings. Although the amendment procedure in Article 138/3 is still not straight forward for IP Courts and the TPMO, IP Courts are increasingly inclined to examine such requests and instruct the TPMO to decide on the limitation.

First Damages Judgement in the Pharma Sector for Unjust PI

In 2018, the Istanbul IP Court decided on a generic company's damages claim based on an unjust PI, in what appears to be the first decision of its kind by the Turkish IP courts within the pharmaceutical sector. This is a first instance court decision, subject to an appeal from parties to the case.

The dispute between an originator firm and a generic firm derived from an infringement claim. The Court had issued a PI, which was lifted after 13 months based on the findings of an experts' report, which found that there had been no infringement. The generic company then filed a compensation action for damages due to the fact that it had not been able to launch the generic product during the 13-month PI term. However, as the generic product was never released to the market – even after the dismissal – it was difficult for the Court appointed experts to calculate the amount of compensation due.

The patent holder argued that in order to calculate the hypothetical market share of the generic company, the Court should compare other similar products across various markets during the same period; it submitted the in-market sales data for two example products, which had a 6.7% and 16% market share as the first generics. It also challenged the generic company's calculation of a 37.5% market share, suggesting that any company used as a model should be of a similar size and reputation in the market, and that the sales should have taken place during the same period.

After reviewing the evidence, the experts calculated the market share based on a comparison of in-market sales data for similar product markets. They also tested different hypothetical scenarios in which the generic firm would have had, for example, a 6.7%, 16%, 37.5% or 50% market share. The experts concluded that the generic firm would most likely to have had 16% market share. Therefore, the court awarded damages based on this figure.

A 'one size fits all' approach for the calculation of damages is not appropriate for this kind of action as certain case-specific parameters must be considered. Among others, these include the conditions for pricing and sales of the products within the relevant period; the therapeutic area of the drug; the size and sales potential of the pharmaceutical company; brand loyalty; and the substitutability of the generic with the original product.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Practice Guides
by Mondaq Advice Centres
Relevancy Powered by MondaqAI
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions